Cancer, a complex and multifactorial disease, presents a significant challenge to global
health. Despite significant advances in surgical, radiotherapeutic and immunological …

Importance Anthracyclines treat a broad range of cancers. Basic and retrospective clinical
data have suggested that use of atorvastatin may be associated with a reduction in cardiac …

Since their introduction in the 1960s, anthracyclines have been a significant breakthrough in
oncology, introducing dramatic changes in the treatment of solid and hematologic …

Background and aims Anthracyclines can cause cancer therapy-related cardiac dysfunction
(CTRCD). We aimed to assess whether statins prevent decline in left ventricular ejection …

Background Sodium glucose cotransporter-2 inhibitors (SGLT2is) are hypothesized to
reduce the risk of anthracycline-associated cardiotoxicity. Objectives This study sought to …

Anthracyclines form the backbone of many chemotherapy protocols and are frequently used
with curative intent in lymphoma, childhood leukemia, breast cancer, and other solid tumors …

Thanks to the fantastic progress in cancer therapy options, there is a growing population of
cancer survivors. This success has resulted in a need to focus much effort into improving the …

Anthracycline chemotherapy causes cardiotoxicity, and the evidence regarding the benefit of
concomitant statin use in reducing it remains uncertain. We conducted a meta-analysis of …

BACKGROUND: Anthracycline-induced cardiotoxicity has a variable incidence, and the
development of left ventricular dysfunction is preceded by elevations in cardiac troponin …

Abstract Background Cardiotoxicity occurs in 5–20% of cancer patients who receive
anthracyclines. The aim of this study was to pool all the randomized controlled trials (RCTs) …